A protein called cyclin E may help breast cancer patients predict whether or not their disease is progressing. High levels of cyclin E have been associated with increased morbidity, while low levels suggest a better chance of recovery. By measuring patients’ levels of cyclin E, doctors may have a better idea of how aggressive treatment needs to be.